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Repeated administration of gene therapies is  hampered 
by host immunity toward vectors and transgenes. 
Attempts to circumvent antivector immunity include 
pharmacological immunosuppression or alternating 
different vectors and vector serotypes with the same 
transgene. Our studies show that B-cell depletion with 
anti-CD20 monoclonal antibody and concomitant T-cell 
inhibition with clinically available drugs permits repeated 
liver gene transfer to a limited number of nonhuman pri-
mates with recombinant adenovirus. Adenoviral vector–
mediated transfer of the herpes simplex virus type 1 
thymidine kinase (HSV1-tk) reporter gene was visual-
ized in vivo with a semiquantitative transgene-specific 
positron emission tomography (PET) technique, liver 
immuno histochemistry, and immunoblot for the reporter 
transgene in needle biopsies. Neutralizing antibody and 
T cell–mediated responses toward the viral capsids were 
sequentially monitored and found to be repressed by 
the drug combinations tested. Repeated liver transfer of 
the HSV1-tk reporter gene with the same recombinant 
adenoviral vector was achieved in macaques undergoing 
a clinically feasible immunosuppressive treatment that 
ablated humoral and cellular immune responses. This 
strategy allows measurable gene retransfer to the liver as 
late as 15 months following the first adenoviral exposure 
in a macaque, which has undergone a total of four treat-
ments with the same adenoviral vector.
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published online 19 January 2010. doi:10.1038/mt.2009.312
IntroductIon
The immune system has been evolutionarily selected to fight 
viruses and is a serious hurdle for gene therapies based on viral 
vectors.1,2 Immunity against the vector precludes readministration 
as reported with recombinant adenovirus3 and adeno-associated 
virus (AAV)–based vectors.4 Attempts to circumvent antivector 
immunity include pharmacological immunosuppression5 or 
alternating different vectors with the same transgene.6 In the case 
of adenoviruses, immunogenicity is very potent and has been 
exploited for vaccination.7,8
Liver tropism of adenoviruses is considered advantageous for 
gene therapy interventions in this organ. This is the case of helper-
 dependent (“gutless”) adenoviruses used to correct inherited 
disorders with a need for sustained expression that necessarily 
require repeated vector administrations.3 Tumoricidal condi-
tionally replicating adenoviruses may need immunosuppression 
to allow the agent to spread sufficiently within the malignancy.9 
Adenoviruses turn on innate immune functions such as type I 
interferon and other proinflammatory cytokines.10–12 Innate 
responses can prime for a humoral immune response generating 
neutralizing antibodies to adenoviral capsid antigens, which are 
augmented by T-cell help.1,2
Visualization and measurements of transgene expression are 
needed to refine and optimize gene therapy strategies. We have 
recently set up in nonhuman primates a semiquantitative trans-
gene-specific positron emission tomography (PET) technique,13 
which allows detection and imaging of the reporter gene herpes 
simplex virus type 1 thymidine kinase (HSV1-tk). HSV1-tk as a 
reporter transgene can be traced by means of PET imaging in non-
human primates13,14 and in humans.15,16 This imaging technique is 
based on measurements of retention of [18F]9-(4-[18F]-fluoro- 3-
hydroxymethylbutyl)-guanine ([18F]FHBG) in the liver parenchyma 
once phosphorylated by HSV1-tk. This noninvasive imaging tech-
nique is useful for assessing the possibility of repeated gene trans-
fer. We reasoned that if first-generation recombinant adenovirus 
could be readministered, it would be easier to repeatedly use less 
immuno genic adenoviral vector generations. An additional advan-
tage of our adenoviral system is the transient time course of trans-
gene expression.15 Once transgene expression is extinguished in 
about 2 weeks, the visualization of the efficiency of subsequent gene 
transfers is experimentally feasible. Transgene expression extinc-
tion is explained by immune elimination of transduced cells and 
gene silencing affecting the cytomegalovirus (CMV) promoter.17
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Many approved drugs exist5,18–22 that thwart the immune 
response and might allow for viral vector readministration. A pre-
vious report23 has shown the feasibility and safety of pharmacolog-
ical immunosuppression of three macaques in an attempt to block 
T-cell responses to AAV encoding factor IX coagulation factor. In 
this study, we have demonstrated that pharmacological immuno-
suppression can achieve repeated liver gene transfer with the same 
first-generation adenoviral vector in spite of the high degree of 
immunogenicity attributed to this viral vector. B-cell depletion 
with anti-CD20 monoclonal antibody19,24 and concomitant T-cell 
inhibition with clinically available drugs permits repeated liver 
gene transfer in macaques.
results
rituximab and FK506 treatment reduce the 
antiadenoviral humoral and cellular immunity that 
prevents gene-transfer repetition with the same vector
To test whether immunosuppression could allow repeated admin-
istration of an adenoviral vector, a group of macaques treated i.v. 
with the clinical-grade first-generation recombinant adenovirus 
AdCMVHSV1.tk25 (Figure 1a) received two courses of Rituximab 
to deplete B cells26 plus a conventional daily oral regimen with 
FK506 (ref. 18) to repress T cells (Figure 1a).
Two doses of AdCMVHSV1-tk were given i.v. 4 weeks apart 
to three macaques. Only two of the animals received immuno-
suppression. PET imaging was performed 2 days after each 
adeno virus administration. The liver of the three animals showed 
evidence of transgene expression following the first administra-
tion, but only one of the immunosuppressed subjects showed a 
certain degree of reexpression upon the second administration 
(Figure 1b,c). To rule out residual transgene expression from 
the first dose of adenovirus, a PET study was performed 1 week 
before the second adenoviral administration. This is shown in 
Supplementary Figure S1a that summarizes the sequential 
PET measurements of transgene expression performed in these 
animals.
In the nonhuman primates, the two-drug regime reduced 
the titer of neutralizing antibodies by one log, but failed to abol-
ish the humoral response (Figure 1d). One potential reason is 
that the depletion of B cells had not been complete as previously 
suggested by other authors.22 In this regard, we found that in 
the  subject who attained HSV1-tk partial reexpression, CD20+ 
B-cells in peripheral blood samples were virtually undetectable 
(Figure 1e). In the other animals treated with the same immu-
nosuppressive regimen, B-cell counts were lowered only about 
2.5 times in comparison to the control macaque (Figure 1e). 
This difference could account for the different gene-transfer 
outcome. Peripheral blood T-lymphocytes (both CD4 and CD8) 
proliferated avidly upon in vitro exposure to adenoviral capsids, 
6 weeks after the first administration (Figure 1f,g). Clearly less 
marked, albeit detectable, proliferation was substantiated in the 
CD4 T-cell compartment of the animal with partial transgene 
reexpression, and it is likely that these T-lymphocytes were still 
providing sufficient help for antibody responses (Figure 1f,g). 
Of note, all the animals tolerated the treatments well with only 
moderate increases of serum liver enzymes (Supplementary 
Figure S1b).
More intensive immunosuppression with rituximab, 
FK506, antithymocyte immunoglobulin, MMF, and 
steroids permit repeated transfer of the HsV1-tk 
transgene
The partial success obtained in our first study (Figure 1) suggest 
that B-22 and T-cell suppression is important for permitting ade-
noviral vector readministration, but that the two-drug  regimen 
may not be sufficient.1 Therefore, we pursued a more intensive 
immunosuppressive protocol. Accordingly, a more intense five-
drug immunosuppression regime was tested in a new group of 
three animals. Antithymocyte immunoglobulin (ATG),19,27 myco-
phenolate mofetil (MMF),28 and steroids were added. The course 
of Rituximab27 was intensified with weekly doses between adeno-
viral administrations. FK506 was given as in the first group of 
macaques (Figure 2a). The goals were to decrease T cells (ATG), 
to prevent B-cell rebounds (with more frequent readministrations 
of Rituximab) and to further inhibit residual B- and T-cell signal-
ing with MMF. Steroids were included mainly to prevent systemic 
inflammatory responses elicited by ATG and in addition methyl-
prednisolone can also diminish the early innate immune response2 
toward the adenoviral capsids.
Preexisting low titers of antiadenovirus antibodies seen in 
patients had not precluded gene transfer upon first intratumoral 
administrations of the vector.15 Such weak reactivity probably 
reflects previous exposure to partially cross-reactive adeno viral 
serotypes. None of the animals in the first group had shown 
this feature (data not shown). However, one of the macaques in 
the second group showed a low titer of pretreatment antibodies 
that fell below the detection threshold in four other sequential 
samples (Figure 2b). In this subject, a weak cellular response 
toward adenoviral capsids was also detected immediately before 
AdCMVHSV1-tk exposure (Figure 2c). None of the other two 
animals showed pretreatment signs of antiadenoviral immunity 
(Figure 2b,c). To study the possible influence of this weak pre-
treatment antiadenoviral immunity, this animal was chosen to 
receive immunosuppression, whereas the other two were ran-
domly distributed to receive or not the five-drug regimen.
Again all the macaques showed intense PET signal following 
the first adenovirus exposure (Figure 2d). Upon second adminis-
tration 1 month later (Figure 2d), one of the immunosuppressed 
macaques remarkably showed liver transgene expression of the 
same order of magnitude as in the previous administration. As 
expected, the control subject did not show reexpression of the 
transgene. This was also the case with the animal which had 
showed low levels of pretreatment antiadenoviral immunity.
In the animal with positive PET signal upon adenoviral 
 readministration, immunohistological (Figure 2e) and immuno-
blot analyses (Figure 2f) on ultrasound-guided needle biopsies 
taken from the right and left liver lobes of the animals confirmed 
the expression of the tk transgene. There were no histological 
signs of liver inflammation although serum transaminases were 
moderately increased (Supplementary Figure S2a,d). Tk was 
present both in parenchymal cells and liver macrophages (Kupffer 
cells) (Figure 2e and Supplementary Figures S2b,c and S4). 
Kupffer cells were identified by morphological criteria and CD68 
immunostaining in serial sections (Supplementary Figure S2c). 
Quantitative analyses 3 days after the adenoviral readministration 
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concluded that about 8% of hepatocytes and virtually all Kupffer 
cells were HSV1-tk+ (Figure 2e). Two nonmutually exclusive pos-
sibilities for the tk presence in Kupffer cells can be considered: 
(i) direct transfection by the adenovirus or (ii) phagocytosis from 
expressing hepatocytes. Phagosome granular images were not 
observed, favoring the former option. Full transduction of liver 
macrophages has important implications for transgene function-
ality and immunogenicity.12,29 This is also important because pre-
vious reports in mice indicate that Kupffer cell depletion increases 
gene transfer to liver parenchyma cells.29
HSV1-tk expression was confirmed by immunoblot in these 
biopsy samples taken from the right and left liver lobes 3 days 
after the second AdCMVHSV1-tk administration (Figure 2f). 
Immunoblot and immunohistochemical tk stainings were 
found negative in the control macaque 004 and treated macaque 
005 (Figure 2e,f), indicating a good correlation with the PET 
results.
B-lymphocyte depletion by Rituximab was far more effec-
tive in the second cohort of animals and B cells remained almost 
undetectable for the duration of the protocol (Figure 3a). CD4 
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Figure 1 Immunosuppression of macaques with rituximab and FK506 partially fails in an attempt to transfer twice a transgene to the liver 
with the same first-generation adenoviral vector. (a) Schematic time line representation of two administrations of a first-generation adenovirus 
encoding HSV1-tk to three female macaques (individually color-coded) and the immunosuppressive treatments given to two of the animals with 
Rituximab (20 mg/kg, i.v.) or daily doses of FK506 during the shaded time (1 mg/day). (b) Positron emission tomography (PET) images from the 
three macaques 2 days after each i.v. administration of AdCMVHSV1-tk performed on the dates marked in a (green arrows) to nonimmunosuppressed 
001 control (black), and those animals receiving the immunosuppressive drugs (002-red, 003-green). PET images monitor [18F]FHBG tracer, which 
becomes phosphorylated and intracellularly retained inside tk-expressing cells. (c) Time course of quantitative analyses of tracer retention in the 
hepatic region during PET analyses in the animals after the first and second dose of the recombinant AdCMVHS1-tk. Values are normalized by sub-
traction of the intensity of baseline positron emission in each macaque as measured 1 week before the administration of adenovirus. (d) Follow-up of 
the titers of neutralizing antiadenoviral antibodies after the first and second administration of AdCMVHSV1-tk to the macaques (color-coded as in a). 
(e) Double immunostainings of CD20+ and CD19+ cells in peripheral blood mononuclear cell (PBMC) from the indicated color-coded macaques in 
blood samples drawn upon termination of the second Rituximab course (13 weeks after the first adenoviral administration). (f) In vitro mitogenic 
responses to adenoviral capsids measured by 3H-Thy incorporation (mean ± SD) of PBMC taken from the indicated macaques (color-coded) 13 weeks 
after the second adenovirus administration. (g) Fluorescence-activated cell-sorting histograms showing proliferation as estimated on gated CD4+ 
and CD8+ lymphocytes by CFSE dilution in response to adenoviral capsids at the same time point as in f. Analyses performed in the indicated 
color-coded macaques. Ad, adenovirus; CFSE, carboxyfluorescein succinimidyl ester; [18F]FHBG, [18F]9-(4-[18F]-fluoro-3-hydroxymethylbutyl)-guanine; 
HSV1-tk, herpes simplex virus type 1 thymidine kinase; gb, gall bladder; i.v., intravenous; lv, liver; nAb, neutralizing antibody; SI, stimulation index.
T-cell counts were maintained low following treatment, although 
CD8 T-cells rebounded faster (Figure 3a). The reduction of lym-
phocyte counts in the control animal (Figure 3a) could reflect 
sequestration in lymphoid organs as is the case in lymphocyto-
penia secondary to acute viral infections.25
Neutralizing antibodies and T-cell responses against adeno-
virus remained very low in the 006 macaque who reexpressed 
the HSV1-tk reporter transgene (Figure 3b,c). In contrast, the 
control subject (004 macaque) and the individual with preex-
isting low adeno viral immunity (005 macaque) produced neu-
tralizing antibodies and anticapsid T-cell responses following 
the first adeno viral administration (Figure 3b,c). Importantly, 
neutralizing antibody titers eventually declined in both immu-
nosuppressed animals but not in the control. Figure 3d,e 
shows proliferation among gated CD4 and CD8 T-cells after 
in vitro exposure to adeno viral capsids in samples obtained 6 
weeks after the second adenoviral administration. In the ani-
mal that reexpressed the transgene, proliferation of both CD4 
and CD8 was ablated, but only partially reduced in the CD4 
compartment of the animal that did not reexpress in spite of 
immunosuppression.
The antibody immune response toward the foreign tk protein 
was undetectable after three administrations of AdCMVHSV1-tk 
by western blot on purified recombinant tk, although the sera 
from the same macaques were readily reactive to adenoviral capsid 
α-fiber (Supplementary Figure S3).
under a discontinuous intensive immunosuppressive 
regimen liver gene retransfer was attained 8 months 
after the first administration of the same adenoviral 
vector
To study whether a third readministration of the same adenovi-
ral vector was feasible, the color-coded macaques of the second 
cohort (Figure 2) were kept off immunosuppressive treatment 
for 4.5 months without signs of disease. Then the immunosup-
pressive regimen was started again in the macaques that had 
previously received the five-drug regimen (Figure 4a). A third 
i.v. administration of AdCMVHSV1-tk was given to the three 
animals (Figure 4a). Upon this third administration of the 
same vector both immunosuppressed animals showed [18F]-
FHBG retention in the liver that was more intense in the ani-
mal that had successfully reexpressed the tk transgene upon the 
first readministration (Figure 4b). Although reexpression was 
more modest in the animal that had shown preexisting adenovi-
ral immunity, transgene-dependent retention of the PET tracer 
was also clearly detected. tk expression by both immunosup-
pressed macaques was confirmed by immunohistochemistry 
and immunoblots (Figure 4c,d) in the corresponding needle 
liver biopsies.
The humoral and cellular response against adenoviral capsids 
had remained suppressed before the third adenoviral readmin-
istration in the immunosuppressed animals but not in the con-
trol macaque (Figure 4e,f). It is of note that following the third 
AdCMVHSV1-tk administration even the immunosuppressed 
animals showed a rise in neutralizing antibodies against adeno-
virus, albeit one or two logs less concentrated in the immunosup-
pressed animals than in the control macaque. In this regard, the 
monkey which had had signs of low adenoviral immunity before 
the protocol showed higher titers at this stage of the experiment. 
The cellular response remained low in the immunosuppressed 
monkeys but was readily detected in the peripheral blood mono-
nuclear cells from the control animal in which it peaked on day 5 
after adenoviral exposure (Figure 4f). In Figure 4g, the numbers 
of T- and B-lymphocytes are recorded during the time around the 
third adenoviral administration.
Figure 5a shows the PET measurements of the second cohort 
color-coded macaques (Figures 2 and 4) to provide a summary 
of the results. Figure 5b shows the time course [18F]-FHBG liver 
uptake in the PET imaging experiments performed 2 days after 
each adenoviral administration.
Moreover, 7 months after this third readministration a 
fourth infusion of the adenoviral vector was given to macaques 
006, which had been weaned from immunosuppression during 
4 months, and the control macaque 004. Importantly, macaque 
006 was free of neutralizing antibodies during the previous month 
before the fourth adenovirus injection, while 004 still maintained 
titers above 1/50,000. As expected, there was expression upon 
immunohistochemical staining for tk in the liver biopsies from 
006 taken 2 days after the fourth AdCMVHSV1-tk injection but 
not in case of macaque 004 (Supplementary Figure S4a–c). At the 
time of the fourth readministration there was a transient and mild 
peak of alanine aminotransferase and aspartate aminotransferase, 
whereas alkaline phosphotase remained normal (Supplementary 
Figure S4d–f).
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Of note, there was an transient peak of interleukin-6, tumor 
necrosis factor-α, and interleukin-1β in the serum of these animals 
within the 24 hours immediately following a readministration 
of AdCMVHSV1-tk (Supplementary Figure S5) that indicated 
activation of an innate immune response. There was a decrease 
of peripheral blood lymphocytes upon adenoviral administration, 
although platelets remained in the normal range. Transient lym-
phopenias (Supplementary Figures S5 and Figures 3a and 4g) 
could be related to lymphocyte sequestration in secondary lym-
phoid organs.
This second cohort of macaques offers a proof-of-the con-
cept that pharmacological immunosuppression may permit gene 
liver retransfer with adenoviral vectors at least for four times.
dIscussIon
This study explores in nonhuman primates the potential of 
immuno suppression to allow repetitive gene transfer with viral 
vectors. The small number of nonhuman primates available pre-
cludes taking the data as definitive evidence, but clearly offers 
a proof-of-the concept to support that strategies combining 
immuno suppression and gene therapy can be feasible and suc-
cessful in at least in some cases. The limits to the size of macaque 
cohorts were imposed by ethical approval and logistics. A ques-
tion that we face now is how much animal experimentation must 
be implemented for optimization of immunosuppression proto-
cols before testing such approach in humans. More of that, taking 
into account that the predictability of the macaque model remains 
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Figure 2 An uninterrupted five-drug immunosuppressive regimen (rituximab+FK506+MMF+AtG+methyl prednisolone) permits efficient 
liver gene-transduction upon a second administration of an adenoviral vector given 1 month later to an adenovirus naive macaque. This was 
not feasible in a macaque with signs of previous weak immunity to the viral vector. (a) Schematic representation of the time course of the experiment 
with the i.v. administrations of AdCMVHSV1.tk that were received by three color-coded macaques and the immunosuppressive regimen given to two 
of the animals when indicated by the corresponding arrows at the following doses: Rituximab (20 mg/kg), antithymocyte γ-globulin (3 mg/ kg), meth-
yl-prednisolone (100 and 50 mg/animal in two daily doses before each adenoviral administration), as well as daily mycophenolate mofetil (30 mg/kg) 
and FK506 (0.25 mg/kg) during the time indicated by the shaded area. (b) Representation of the pretreatment baseline responsiveness of the color-
coded animals to adenoviral capsids as detected by the presence of neutralizing antibodies and (c) PBMC proliferation to serial dilutions of adenoviral 
capsids performed 2 weeks before the first infusion of AdCMVHSV1-tk. (b) One of the animals (color-coded red) showed low titer antibodies 30 
weeks before first adenoviral vector treatment, which became negative in sequential determinations thereafter and (c) low level of antiadenoviral 
lymphocyte proliferation 10 days before the first administration of adenovirus. (d) Coronal 1 mm-thick positron emission tomography (PET) images 
from the three macaques 2 days after each intravenous administration of AdCMVHSV1-tk performed on the dates marked in a to nonimmunosup-
pressed [004 control (black)], and those animals receiving the immunosuppressive drugs [005-red, 006-green]. PET images monitor [18F]FHBG tracer 
which becomes phosphorylated and intracellularly retained inside tk-expressing cells. Gall bladder (gb) accumulation shows hepatobiliary clearance 
of the tracer. Dotted lines outline an approximate contour of the liver (lv) based on 3D stacked PET images. (e) Percentage of tk+ cells in ultrasound-
guided needle biopsies taken from the right and left liver lobes of the color-coded macaques upon immunohistochemistry stainings. Quantitative 
data were generated by computer assisted image analyses of 8 non-serial slides counting >1,000 cells. Liver macrophages were distinguished by 
morphology confirmed with CD68 immunostaining (Supplementary Figure S2c). In the positive macaque a second biopsy performed on day 
17 after the second adenoviral administration and showed transgene expression extinction (day +17). (f) Immunoblot analysis of tk and GAPDH 
(house keeping control) on liver tissue homogenates from the liver biopsies. As a positive control COS7 cells transduced with AdCMVHSV1-tk were 
used. L and R indicate the hepatic lobe (left and right, respectively) from which the punch biopsy were taken. An additional biopsy was performed 
2 weeks after the first set of biopsies (day +17) to assess persistence of expression in the animal successfully retransduced with tk (color-coded green). 
To corroborate transgene extinction an extra PET study performed one day before that biopsy was negative (images not shown are summarized in 
Figure 5). Ad, adenovirus; ATG, antithymocyte immunoglobulin; [18F]FHBG, [18F]9-(4-[18F]-fluoro-3-hydroxymethylbutyl)-guanine; i.v., intravenous; 
MMF, mycophenolate mofetil; nAb, neutralizing antibody; PBMC, peripheral blood mononuclear cell; SI, stimulation index.
largely undefined in this type of experimentation, macaque safety 
and efficacy results should be taken with caution.
The liver is a preferred target organ for gene therapy not 
only for liver-specific diseases but also for disorders that require 
systemic delivery of a protein. The pharmacology of immuno-
suppression is fast advancing and gene therapy may benefit from 
it, as has been the case in organ transplantation. Rituximab is a 
B-cell-depleting anti-CD20 fully human monoclonal antibody 
that is widely used for the treatment of Non-Hodgkin B-cell lym-
phomas.24 Additionally, it has demonstrated efficacy in various 
autoimmune conditions30,31 and a promising role for allogenic tis-
sue grafting.19 At the beginning of this project, we reasoned that 
if repeated liver gene transfer with adenovirus vectors was impos-
sible mainly because of neutralizing antibodies, the depletion of 
B lymphocytes should be helpful to repeat gene transfer. The side 
effects of Rituximab in humans24 are quite tolerable and the ensu-
ing humoral immunodeficiency, if serious, should be reversible by 
immunoglobulin infusions.
High avidity neutralizing antibodies need T–B cell coopera-
tion32 and therefore a daily course of the calcineurine inhibitor 
FK506 was considered adequate to prevent T-cell activation in 
this regard. The results in the first cohort of macaques indicated 
that this two-drug regimen reduced humoral and cellular immu-
nity directed to the viral capsids, albeit the overall pharmacologi-
cal effect was not intense enough as to both completely suppress 
the immune response and allow successful subsequent gene 
transfer.
The obvious next step was to enhance the intensity of the 
immunosuppressant cocktail. With these ideas in mind, a much 
stronger pharmacological regimen was given to a second cohort 
of macaques including drugs that drastically, but transiently 
diminish T-cell counts and reactivity. ATG would decrease num-
bers of circulating T-cells,33 and MMF would repress signaling in 
B- and T-lymphocytes.34 Steroids were given immediately before 
each administration of ATG and adenovirus to mitigate possible 
systemic inflammation. This regimen controlled both the cellular 
and humoral response more efficaciously. In an animal without 
previous signs of immunoreactivity to viral capsids, this resulted 
in complete success upon readministration up to four times over 
a 15-month period. Interestingly, in this animal each success-
ful gene retransfer coincided in time with transient increases in 
transaminases (~2 days after adenoviral administration) that may 
indicate some hepatocyte cytolysis also seen at lower levels in the 
nonimmuno suppressed controls.
Preexisting immunity might be less amenable to be restrained 
by pharmacological immunosuppression. Pretreatment plasma-
pheresis to remove antibodies could be considered. Lack of effect 
of Rituximab on plasma cells35 is a hurdle because of their role 
as long-lasting sources of antibody that remain in the anti-CD20 
monoclonal antibody treated subjects.36
It is intriguing that primary gene transfer under immunosup-
pressive treatments tended to attain less efficiency in transgene 
expression as assessed by PET. We do not understand the rea-
sons, but intriguingly the group of Katherine High has observed 
a similar phenomenon in animals undergoing different immu-
nosuppressive regimens and transduced in the liver with AAV 
vectors (ref. 37 and K. High, Children’s Hospital, University of 
Pennsilvania, personal communication, 24 November 2009). We 
are currently experimentally addressing this phenomenon in 
murine models.
Repeated liver gene therapy can be highly efficacious for con-
ditions such as hemophilia,37 familiar hypercholesterinemia,38 gly-
cogen storage diseases,39 phenylketonuria,40 hepatic porphyrias,41 
etc. Likewise it is possible that tumor-selective oncolytic adenovi-
rus could become more efficacious and be successfully readmin-
istered under this kind of pharmacological immunosuppression 
protocols.42 Ongoing experiments in our institution will address 
the role of transient pharmacological immunosuppression to per-
mit readministration of gutless adenoviral vectors that are being 
developed to correct liver metabolic diseases.
In the case of AAV, it has been seen that clearance of transduced 
hepatocytes is mediated by a CD8 T-cell response that recognizes 
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the internalized capsid antigens.4,23,43 The situation with adenoviral 
vectors may be different and highly modulated by the fact that liver 
macrophages are readily infected by adenovirus to the point that, 
according to our immunohistochemistry data, most Kupffer cells 
express the transgene.29,44 We have examined the humoral immune 
response to HSV-tk without finding specific antibodies in serum 
but the cellular immune response toward the product of this trans-
gene could not be measured for technical limitations.
Strikingly, despite intensive immunosuppression, a macaque 
with weak signs of preexisting adenoviral immunity was not suc-
cessfully retransferred 4 weeks following the first exposure to 
the viral vector and only attained partial reexpression following 
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a third administration given 4 months later. Interestingly, in this 
macaque neutralizing antibodies were below the detection thresh-
old at the time of first exposure to the vector, but T-cell reactivity 
was still measurable in its peripheral blood, pointing once again to 
the key role played by T-lymphocytes. This macaque with low pre-
existing adenoviral immunity provides a clue to a situation of low 
titer antiadenoviral antibodies that is commonly found in human 
beings.15 Intratumoral readministration of the same adenoviral 
vector to patients with liver cancer has been reported as being 
fruitless in terms of transgene reexpression because of neutraliz-
ing antibodies.15 But in these patients low preexisting immunity 
did not prevent gene transduction following the first vector dose. 
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In agreement with these observations, low levels of preexisting 
immunity did not preclude transgene expression upon the first 
dose of AdCMVHSV1-tk to the macaque.
It is worth noting that a similar immunosuppressive regimen is 
under clinical trial (NCT 00782821). Importantly, no overt infec-
tious complications were observed and all our animals were alive 
15 months after the first adenoviral dose and lymphocyte counts 
returned to normal when the treatment was discontinued. This 
indicates that strong combined T- and B-cell immunosuppression 
if maintained for a 3–4 month period is relatively safe.19 Longer 
immunosuppressive maintenances are likely to be problematic as 
is the case in transplantation patients and in a gene therapy patient 
treated with an AAV encoding a tumor necrosis factor-α antag-
onist transgene.45 An aspect to be taken into account is that the 
functional thymus in macaques at this age facilitates the repopula-
tion of the T-cell compartment.
Considering the risks, serious opportunistic infections 
could be eventually palliated in this therapeutic setting with 
exogenous infusions of immunoglobulins or cryopreserved self 
T-lymphocytes frozen and stored before treatment. On the other 
side, pharmacological immunosuppression could have affected 
the early cytokine response that is detected following adenovirus 
injections.10,12,46 If exacerbated, such innate response is a well-
known mediator of severe acute toxicity.47 However, our data on 
interleukin-6 and tumor necrosis factor-α serum concentrations 
fortunately indicate that there are no signs of such an augment, at 
least in the tested conditions.
Risk must be balanced in terms of the expected benefit and the 
available alternatives for the patients. In this sense, the concept of 
acceptable risk in gene therapy is to be refined and depends on the 
outcome of the disease, existence of alternative treatments, and the 
expected benefit.48 What is clear is that immunological end points 
are to be included is the clinical trials to optimize immunosup-
pression regimens. This is because immune parameters correlate 
with successful repeated gene transfer according to our results.
Research on the persistence of adenoviral antigens under 
immunosuppressive regimens will determine just how long 
immunosuppressive therapy will need to be continued. It is con-
ceivable that if antibodies are a major driving force for clearing 
the capsid proteins, such proteins may persist much longer under 
B-cell suppression.
It is likely that immunosuppression requirements will be less 
demanding for less immunogenic helper-dependent adenoviruses. 
Noninvasive PET imaging can be a useful tool to evaluate the fea-
sibility of readministrations in the clinical arena when combining 
a reporter and a therapeutic gene.
All in all, our results in a limited number of nonhuman 
primates indicate that comprehensive T- and B-cell transient 
pharmacological suppression can overcome the obstacles to read-
ministration of adenoviral vectors used in gene therapy and have 
clear potential for clinical applications.
MAterIAls And MetHods
Animals. Three-year-old captive bred female nonhuman primates 
(Macaca fascicularis) were purchased from R.C. Hartelust (Tilburg, The 
Netherlands). Animal experiments were performed following a protocol 
previously approved by the Ethics and Biosafety Committee according 
to guidelines from the University of Navarra and government of Navarra 
with emphasis in the reduce, replace and refine standards which prevented 
enlargement in the number animals involved in this protocol. Before the 
studies, macaques underwent complete physical and biochemical exami-
nations, evaluation of clinical pathology parameters and were screened for 
tuberculosis. Biochemical parameters in serum were measured in a Cobas 
Integra 400 (Roche Diagnostics, Barcelona, Spain). Platelet and blood 
cell counts were performed in an automated Sysmex XT-1800i (Sysmex 
America, Mundelein, IL) with software set-up for macaque analysis.
Vector infusion procedure. A first-generation clinical-grade recombi-
nant adenovirus encoding tk (AdCMVHSV1-tk) has been described.25 
Adenovirus was diluted in phosphate-buffered saline to a final volume of 
10 ml and slowly infused to the anesthetized animal via a peripheral vein at 
1.4 × 1012 viral particles per dose.
Immunomodulation therapy. Immunosuppressants were administered 
as described in Figures 1a and 2a. Two-drug regimens consisted of (i) 
20 mg Rituximab/kg/dose intravenously (i.v.) (Mabthera, ROCHE, Basel, 
Switzerland) at days −9, −6, −3 and immediately before adenovirus injec-
tions; and (ii) Tacrolimus (FK506; Astellas Pharma, Madrid, Spain) at a 
dose of 0.25 mg/kg administered orally from day −2 and daily to the end of 
the study (Figure 1a). The five-drug regime included (i) Rituximab (20 mg/
kg/dose i.v.) at days −9, −6, −3, immediately before adenovirus injections 
and weekly after the viral administration, (ii) two doses of 3 mg/kg of rab-
bit ATG (Genzyme Polyclonals, Marcy l’Etoile, France) at days −2 and −1 
before the adenovirus injection. (iii) Methyl-prednisolone (Solu-moderin, 
Pfizer SA, Spain) was applied intramuscularly 10 minutes before the ATG 
infusion at a dose of 100 mg on day −2 and 50 mg on day −1. (iv) MMF 
(CellCept; Roche Pharma, Madrid, Spain) at a dose of 25–30 mg/kg/day, 
and (v) FK506 0.25 mg/kg/day. MMF and FK506 were orally given from 
day −2 daily during the indicated periods (Figure 2a).
PET analysis. Transgene expression in the liver parenchyma was visu-
alized and quantified by PET13 1 week before and 48 hours after the 
AdCMVHS1-tk administration (“PET analyses of HSV1-tk expression” in 
Supplementary Materials and Methods).
Neutralizing antibody assays49 to AdCMVHSV1-tk. Serial dilutions 
of macaque serum starting from 1/25 were mixed with 1 × 105 plaque-
 forming units of Ad5CMV-luc encoding firefly luciferase (a similar recom-
binant adenovirus also based on serotype 5 backbone) and incubated at 
37 °C for 1 hour then the mixture was added to PCL-PRF5 cells (1 × 104 
cells/well) in a 96-well plate. Forty-eight hours later, cells were washed in 
phosphate-buffered saline and d-luciferin substrate (Xenogen, Alameda, 
CA) was added at a final concentration of 150 μg/ml and placed in a 
light-tight chamber. The intensity of light emission from individualized 
wells was detected using the IVIS cooled charge-coupled device camera 
(Xenogen) and Living Image 2.20 software package (Xenogen). Sera were 
scored as  positive if the light intensity was 50% when compared to negative 
control sera. A curve was adjusted to extrapolate the serum  dilution for 
50% inhibition (IC50).
Fluorescence-activated cell-sorting analysis of the lymphocyte popula-
tions and cytokine serum concentrations. The percentage of B, CD4, and 
CD8 lymphocytes in peripheral blood was determined by flow cytometry 
as detailed in “FACS analysis” in Supplementary Materials and Methods. 
Serum concentrations of cytokines were measured with a BD Cytometric 
Bead Array (Inflammatory Cytokine Kit, Ref.: 551811) analyzed in a 
FACSCalibur (Brussels, Belgium). Culture supernatants of macaque lym-
phocytes stimulated with Concanavalin-A at 1 μg/ml (Sigma, St Louis, 
MO) were used as a positive control.
In vitro evaluation of the cellular immune response against the ade-
noviral vector. To functionally evaluate the cellular immune response 
induced against the vector a number of techniques were set up as detailed 
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in “Measurement of cellular immune responses against adenoviral vector” 
in Supplementary Materials and Methods.
Immunoblot for HSV1-tk expression in liver biopsies, liver histology, 
and immunohistochemical analysis. Western blot analyses were carried 
out to detect HSV1-tk expression in liver tissue biopsies using GAPDH 
as a housekeeping internal control as detailed in “Western blot analysis 
of liver biopsies” in Supplementary Materials and Methods and ref. 
13. Histological analysis of the liver was carried out on 3-µm paraffin-
 embedded sections. Hematoxylin–eosin stain was used to determine 
structure. Immunohistochemical analyses were carried out as detailed in 
“Immunohistochemistry of liver biopsies”in Supplementary Materials 
and Methods. HSV-tk production in eukaryotic cells with a Semliki forest 
virus-based expression system50 to screen by immunoblot for anti-tk anti-
bodies was performed as described in “Construction of SFV-histk vector” 
and “Transfection of cells for TK production” in Supplementary Materials 
and Methods.
suPPleMentAry MAterIAl
Figure S1. Summary of tk expression data and well-being from 
 macaques in the three-drug cohort.
Figure S2. Histological images from the biopsies presented in 
 figure 2.
Figure S3. Anti-tk antibodies in the treated macaques.
Figure S4. Ultrasound-guided liver biopsies were performed from the 
left and right liver lobes of macaques 004 and 006 two days after the 
fourth adenovirus administration.
Figure S5. Platelets and serum inflammatory cytokines following 
 adenoviral administration.
Materials and Methods.
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